Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10005124 | 0.85 | HTR7 (0.36) | MBOAT4HTR7KCNH2KDM1AMAOA | |
| SCHEMBL29994742 | 0.83 | KCNH2 (0.38) | KCNH2IRAK4BACE1PREPDUT | |
| SCHEMBL379113 | 0.83 | KCNH2 (0.38) | KCNH2IRAK4BACE1PREPDUT | |
| SCHEMBL17441587 | 0.82 | KCNH2 (0.39) | MBOAT4HTR7KCNH2DUT | |
| SCHEMBL20436437 | 0.81 | KDM1A (0.39) | KCNH2IRAK4KDM1AMAOAMAOB | |
| SCHEMBL20436590 | 0.81 | KCNH2 (0.39) | KCNH2IRAK4BACE1PARP1DUT | |
| SCHEMBL15968790 | 0.81 | MEN1 (0.39) | MBOAT4KCNH2IRAK4KDM1AMAOA | |
| SCHEMBL28521511 | 0.81 | IRAK4 (0.36) | KCNH2IRAK4BACE1DUT | |
| SCHEMBL5466523 | 0.81 | KCNH2 (0.39) | KCNH2IRAK4BACE1 | |
| SCHEMBL20416847 | 0.81 | KCNH2 (0.39) | KCNH2IRAK4BACE1PREPDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-4581032-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025104236-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-05-22 | — | — | WO | disclosed |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-116981669-B | Pyrimidine or pyrido heterocyclic adenosine receptor inhibitor, preparation method and application thereof | 上海齐鲁制药研究中心有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-113748110-B | Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-114302886-B | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2005012323-A2 | COMPOUNDS USEFUL AS A3 ADENOSINE RECEPTOR AGONISTS | TRIGEN LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| EP-1469864-A1 | COMPOUNDS USEFUL AS A-3 ADENOSINE RECEPTOR AGONISTS | MUSCAGEN LIMITED (GB) | 2004-10-27 | — | — | EP | disclosed |
| US-6727254-B2 | 8-(BIS-(PHENYL) METHYL)-3-HETEROARYL-8-AZABICYCLO-(3.2.1)OCTAN-3-OLS AND DERIVATIVES, USEFUL IN TREATING PAIN, ANXIETY, COUGH, ASTHMA, DEPRESION AND ALCOHOL ABUSE | SCHERING CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040043982-A1 | Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2004-03-04 | — | — | US | disclosed |
| WO-2003061670-A1 | COMPOUNDS USEFUL AS A3 ADENOSINE RECEPTOR AGONISTS | MUSCAGEN LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2002042305-A1 | NITROGEN SUBSTITUTED 1,2,4-TRIAZOLO[3,4-A]PHTHALAZINE DERIVATIVES FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-30 | — | — | WO | disclosed |
| EP-0788497-B1 | BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC (CA) | 2001-05-23 | — | — | EP | disclosed |
| US-5552437-A | ANTIASTHMATIC, ANTIALLERGIC, ANTIINFLAMMATORY, AND CYTOPROTECTIVE AGENTS | MERCK FROSST CANADA, INC. (CA) | 1996-09-03 | — | — | US | disclosed |
| WO-1996013500-A1 | BISARYLCARBINOL DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | MBOAT4 2537/4885HTR7 585/4885KCNH2 4619/4885 |
| US-20040043982-A1 | Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition | PSEN1, BDNF, H1-5 | MBOAT4 4592/4885HTR7 330/4885KCNH2 1381/4885 |
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | MBOAT4 4806/4885HTR7 1637/4885KCNH2 4207/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | MBOAT4 3919/4885HTR7 251/4885KCNH2 294/4885 |
| US-20260055108-A1 | TRIAZINE COMPOUNDS AND USES THEREOF | CBR1, CNR1, CBR3 | MBOAT4 3682/4885HTR7 941/4885KCNH2 194/4885 |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OPRK1 | MBOAT4 3017/4885HTR7 363/4885KCNH2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.